ArticleCancer discovery2019
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
Abstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 331 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
331citing papers in PubMed, 2 pooled it
14.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
331 citing papers in PubMed, 2 syntheses or guidelines pooled it, 500 citations in OpenAlex.
- Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.Frontiers in immunology · 2025Pooled it
- Pooled it
- Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts.Acta oncologica (Stockholm, Sweden) · 2026Article
- The cGAS-STING/MITA pathway in innate antiviral immunity and beyond.Cell insight · 2026Review
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- The cGAS-STING pathway: mechanistic basis, dual biological functions and translational therapeutic advances.Apoptosis : an international journal on programmed cell death · 2026Review
- PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer.Cell reports. Medicine · 2026Article
- Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer.The Journal of biological chemistry · 2026Article
- Review
- DNMT1 is associated with QDPR downregulation and chemotherapy response in lung adenocarcinoma.Medical oncology (Northwood, London, England) · 2026Article
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Residual Lung Cancer After Incomplete Microwave Ablation Exhibits cGAS-STING-ZEB1-Driven Malignant Progression.Cancers · 2026Article
- Extracellular vesicle-mediated suppression of macrophage STING signaling promotes immune dysfunction in dedifferentiated liposarcoma.bioRxiv : the preprint server for biology · 2026Article
- Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling.International journal of molecular sciences · 2026Review
- Fibroblast-specific ablation of MHC-I antigen presentation via the IGF2 axis cripples CD8Science advances · 2026Article
- Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.Cancer immunology research · 2026Article
- Targeting non-small cell lung cancer: Molecular mechanisms and clinical studies (Review).Oncology letters · 2026Review
- Molecular mechanisms regulating cGAS/STING activation in health and disease.The Journal of clinical investigation · 2026Review
- Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer.Nature communications · 2026Article
- From energy metabolic homeostasis to immune remodeling: the role and therapeutic potential of STING signaling in the tumor microenvironment.Cell communication and signaling : CCS · 2026Review
271 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 7 institutions in 3 countries.
Shunsuke KitajimaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Elena IvanovaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sujuan GuoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ryohei YoshidaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Marco CampisiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shriram K SundararamanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-6686-6945
Shoichiro TangeDepartment of Human Genetics, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan.
Yoichiro MitsuishiDepartment of Respiratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Tran C ThaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sayuri MasudaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Brandon P PielDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Paul T KirschmeierDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cloud P PaweletzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hideo WatanabeTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Mamiko YajimaMCB Department, Brown University, Providence, Rhode Island.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. dbarbie@partners.org.
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USBrown University · USIcahn School of Medicine at Mount Sinai · USJuntendo University · JPPolitecnico di Torino · ITTokushima University · JP
Funding
StructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2012 to 2021
$17.8MTargeting the cytokine circuitry of KRAS-driven lung cancerR01CA190394 · NCI · DANA-FARBER CANCER INST · PI David A Barbie · 2015 to 2026
$4.5MDevelopment of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint BlockadeU01CA214381 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BARBIE, DAVID A, KAMM, ROGER D · 2017 to 2021
$3.5MLocalized mRNA translation on the spindle -an essential mechanism for embryonic cell regulationR01GM126043 · NIGMS · BROWN UNIVERSITY · PI YAJIMA, MAMIKO · 2018 to 2022
$2.0MNCI NIH HHS P01 CA154303NCI NIH HHS R01 CA190394NCI NIH HHS U01 CA214381NIGMS NIH HHS R01 GM126043
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene DeletionSignal TransductionAdenocarcinomaAMP-Activated Protein Kinase KinasesCell Line, TumorGene Expression Regulation, NeoplasticHumansInterferon Regulatory Factor-3Lung NeoplasmsMembrane ProteinsMutationProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STAT1 Transcription FactorSTING ProteinAMP-Activated Protein Kinase KinasesInterferon Regulatory Factor-3IRF3 protein, humanKRAS protein, humanMembrane ProteinsProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STAT1 protein, humanSTAT1 Transcription FactorSTING1 protein, humanSTING ProteinSTK11 protein, humanTBK1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.